311 related articles for article (PubMed ID: 25179520)
1. Ex vivo reversal of the anticoagulant effects of edoxaban.
Halim AB; Samama MM; Mendell J
Thromb Res; 2014 Oct; 134(4):909-13. PubMed ID: 25179520
[TBL] [Abstract][Full Text] [Related]
2. Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agents.
Fukuda T; Honda Y; Kamisato C; Morishima Y; Shibano T
Thromb Haemost; 2012 Feb; 107(2):253-9. PubMed ID: 22186946
[TBL] [Abstract][Full Text] [Related]
3. Ex vivo reversal of the anticoagulant effects of edoxaban - comments on the study by Halim et al.
Marlu R; Polack B; Pernod G
Thromb Res; 2015 Mar; 135(3):571. PubMed ID: 25628140
[No Abstract] [Full Text] [Related]
4. Andexanet alfa effectively reverses edoxaban anticoagulation effects and associated bleeding in a rabbit acute hemorrhage model.
Lu G; Pine P; Leeds JM; DeGuzman F; Pratikhya P; Lin J; Malinowski J; Hollenbach SJ; Curnutte JT; Conley PB
PLoS One; 2018; 13(3):e0195122. PubMed ID: 29590221
[TBL] [Abstract][Full Text] [Related]
5. Reversal of apixaban induced alterations in haemostasis by different coagulation factor concentrates in patients after hip or knee replacement surgery.
Schmidt K; Krüger K; Langer E; Schmutzler M; Johnen E; Wernecke KD; von Heymann C; Körber MK
Blood Transfus; 2019 Mar; 17(2):157-162. PubMed ID: 29757137
[TBL] [Abstract][Full Text] [Related]
6. Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor.
Elg M; Carlsson S; Gustafsson D
Thromb Res; 2001 Feb; 101(3):145-57. PubMed ID: 11228338
[TBL] [Abstract][Full Text] [Related]
7. Comparison of antithrombotic and hemorrhagic effects of edoxaban, a novel factor Xa inhibitor, with unfractionated heparin, dalteparin, lepirudin and warfarin in rats.
Morishima Y; Honda Y; Kamisato C; Shibano T
Thromb Res; 2013 Aug; 132(2):234-9. PubMed ID: 23768448
[TBL] [Abstract][Full Text] [Related]
8. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux.
Samama MM; Mendell J; Guinet C; Le Flem L; Kunitada S
Thromb Res; 2012 Apr; 129(4):e77-82. PubMed ID: 21851967
[TBL] [Abstract][Full Text] [Related]
9. The impact of a three-factor prothrombin complex concentrate on the anticoagulatory effects of the factor Xa inhibitor edoxaban.
Brown KS; Wickremasingha P; Parasrampuria DA; Weiss D; Kochan J; Dishy V; He L; Shi M
Thromb Res; 2015 Oct; 136(4):825-31. PubMed ID: 26298619
[TBL] [Abstract][Full Text] [Related]
10. Impact of nonsynonymous mutations of factor X on the functions of factor X and anticoagulant activity of edoxaban.
Noguchi K; Morishima Y; Takahashi S; Ishihara H; Shibano T; Murata M
Blood Coagul Fibrinolysis; 2015 Mar; 26(2):117-22. PubMed ID: 24911450
[TBL] [Abstract][Full Text] [Related]
11. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
Grottke O; van Ryn J; Spronk HM; Rossaint R
Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
[TBL] [Abstract][Full Text] [Related]
12. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
13. Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay.
Morishima Y; Kamisato C
Am J Clin Pathol; 2015 Feb; 143(2):241-7. PubMed ID: 25596250
[TBL] [Abstract][Full Text] [Related]
14. Prothrombin complex concentrate versus recombinant factor VIIa for reversal of coumarin anticoagulation.
Dickneite G
Thromb Res; 2007; 119(5):643-51. PubMed ID: 16842841
[TBL] [Abstract][Full Text] [Related]
15. Edoxaban: Impact on routine and specific coagulation assays. A practical laboratory guide.
Douxfils J; Chatelain B; Chatelain C; Dogné JM; Mullier F
Thromb Haemost; 2016 Jan; 115(2):368-81. PubMed ID: 26510969
[TBL] [Abstract][Full Text] [Related]
16. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
[TBL] [Abstract][Full Text] [Related]
17. Darexaban: anticoagulant effects in mice and human plasma in vitro, antithrombotic effects in thrombosis and bleeding models in mice and effects of anti-inhibitor coagulant complex and recombinant factor VIIa.
Kaku S; Suzuki M; Saitoh M; Funatsu T; Uemura T; Suzuki K; Iwatsuki Y; Kawasaki T
Thromb Res; 2013 May; 131(5):450-6. PubMed ID: 23591155
[TBL] [Abstract][Full Text] [Related]
18. In vitro reversal of supratherapeutic rivaroxaban levels with coagulation factor concentrates.
Körber MK; Langer E; Kaufner L; Sander M; Von Heymann C
Blood Transfus; 2016 Sep; 14(5):481-6. PubMed ID: 27177413
[TBL] [Abstract][Full Text] [Related]
19. Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults.
Samama MM; Kunitada S; Oursin A; Depasse F; Heptinstall S
Thromb Res; 2010 Oct; 126(4):e286-93. PubMed ID: 20807664
[TBL] [Abstract][Full Text] [Related]
20. Multimodal assessment of non-specific hemostatic agents for apixaban reversal.
Martin AC; Gouin-Thibault I; Siguret V; Mordohay A; Samama CM; Gaussem P; Le Bonniec B; Godier A
J Thromb Haemost; 2015 Mar; 13(3):426-36. PubMed ID: 25630710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
